Certara, Inc.
NASDAQ:CERTMedical - Healthcare Information Services
-$0.31 today
- Market cap
- $1.71B
- Beta
- 1.49
- P/E (TTM)
- -59.8
- EPS (TTM)
- -$0.10
Volume 1.75M
Average 4.01M
CERT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Certara, Inc.NASDAQ: CERT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $12.29M rose 16.8% year over year, behind the +20.1% change in trailing-twelve-month research & development. Sequentially, it rose 8.9% from the prior quarter. Over 3 fiscal years it compounded at +13.3% a year.
Context
- Research & development amounted to 9.8% of revenue in FY2025, up 0.2 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +16.8% toward the trailing-twelve-month pace of +20.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 41.04M USD
- Year-over-year change
- +10.6%
- 4-year CAGR
- +19.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.04M | +10.6% |
| FY2024 | 2024-12-31 | 37.11M | +8.6% |
| FY2023 | 2023-12-31 | 34.17M | +21.2% |
| FY2022 | 2022-12-31 | 28.21M | +38.4% |
| FY2021 | 2021-12-31 | 20.38M | — |
Research & Development vs competitors
How CERT compares with its peers on the latest reported figures
- CERT's LTM Mar 2026 research & development of $42.8M is the 2nd highest of the 3 companies compared; the peer median is $84.83M.
- Its year-over-year change of +20.1% is the 2nd highest of 3, against a peer median of +9.0%.
- Research & development amounts to 10.2% of revenue for CERT, versus a peer median of 35.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $160.31M | -11.5% | +11.1% | 59.6% | |
| LTM Mar 2026 | $42.8M | +20.1% | +13.3% | 10.2% | |
| LTM Feb 2026 | $9.34M | +29.5% | +29.0% | 11.6% | |
| Peer median (excluding CERT) | $84.83M | +9.0% | +20.0% | 35.6% | |
Competitors are the stored peer set for CERT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 286.1M | 335.64M | 354.34M | 385.15M | 418.84M |
| Cost of Revenue | 111.62M | 132.58M | 141.02M | 154.52M | 161.13M |
| Gross Profit | 174.49M | 203.07M | 213.32M | 230.63M | 257.71M |
| Gross Margin | 61.0% | 60.5% | 60.2% | 59.9% | 61.5% |
| Research & Development | 20.38M | 28.21M | 34.17M | 37.11M | 41.04M |
| Selling, General & Admin | 99.68M | 99.18M | 127.41M | 120.97M | 139.1M |
| Operating Expenses | 160.91M | 170.55M | 254.09M | 232.36M | 236.7M |
| Depreciation & Amortization | 45.12M | 52.47M | 56.07M | 68.03M | 56.56M |
| EBITDA | 58.58M | 89M | 23.84M | 72.37M | 83.91M |
| EBITDA Margin | 20.5% | 26.5% | 6.7% | 18.8% | 20.0% |
| Operating Income | 13.58M | 32.52M | (40.77M) | (1.73M) | 21.02M |
| Operating Margin | 4.7% | 9.7% | -11.5% | -0.4% | 5.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 16.84M | 17.77M | 22.92M | 21.52M | 19.74M |
| Other Income / Expenses | (16.95M) | (13.77M) | (14.37M) | (15.45M) | (13.4M) |
| Income Before Tax | (3.38M) | 18.76M | (55.14M) | (17.18M) | 7.62M |
| Pre-Tax Margin | -1.2% | 5.6% | -15.6% | -4.5% | 1.8% |
| Income Tax Expense | 9.89M | 4.02M | 214K | (5.13M) | 9.21M |
| Net Income | (13.27M) | 14.73M | (55.36M) | (12.05M) | (1.6M) |
| Net Margin | -4.6% | 4.4% | -15.6% | -3.1% | -0.4% |
| EPS (Basic) | (0.09) | 0.09 | (0.35) | (0.08) | (0.01) |
| EPS (Diluted) | (0.09) | 0.09 | (0.35) | (0.08) | (0.01) |
| Weighted Avg Shares | 149.84M | 156.88M | 158.94M | 160.39M | 160.39M |
| Weighted Avg Shares (Diluted) | 149.84M | 159.35M | 158.94M | 160.39M | 160.39M |
Certara, Inc.
NASDAQ:CERT
Intrinsic Alpha fair value
Locked
Current Price
$11.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.